[go: up one dir, main page]

EE200000186A - Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend - Google Patents

Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend

Info

Publication number
EE200000186A
EE200000186A EEP200000186A EEP200000186A EE200000186A EE 200000186 A EE200000186 A EE 200000186A EE P200000186 A EEP200000186 A EE P200000186A EE P200000186 A EEP200000186 A EE P200000186A EE 200000186 A EE200000186 A EE 200000186A
Authority
EE
Estonia
Prior art keywords
pharmaceutical
particle
preparing
particles
preparation
Prior art date
Application number
EEP200000186A
Other languages
English (en)
Inventor
Elvire Colette Baert Lieven
Verreck Geert
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200000186A publication Critical patent/EE200000186A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200000186A 1997-11-03 1998-10-27 Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend EE200000186A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203407 1997-11-03
PCT/EP1998/006998 WO1999022738A1 (en) 1997-11-03 1998-10-27 Compositions of lipid lowering agents

Publications (1)

Publication Number Publication Date
EE200000186A true EE200000186A (et) 2001-04-16

Family

ID=8228898

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000186A EE200000186A (et) 1997-11-03 1998-10-27 Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend

Country Status (20)

Country Link
US (1) US6342245B1 (et)
EP (1) EP1028730B1 (et)
JP (1) JP2001521899A (et)
KR (2) KR20010023661A (et)
CN (1) CN1278175A (et)
AR (1) AR013739A1 (et)
AT (1) ATE216238T1 (et)
AU (1) AU746890B2 (et)
BG (1) BG104338A (et)
BR (1) BR9814109A (et)
CA (1) CA2307097A1 (et)
DE (1) DE69804994D1 (et)
EE (1) EE200000186A (et)
HU (1) HUP0004139A3 (et)
NO (1) NO20002279L (et)
NZ (1) NZ503413A (et)
PL (1) PL340305A1 (et)
SK (1) SK5972000A3 (et)
WO (1) WO1999022738A1 (et)
ZA (1) ZA989997B (et)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
US20030059487A1 (en) * 2001-09-21 2003-03-27 Niazi Sarfaraz K. Composition and method for the treatment of hypercholesterolemia and hyperlipidemia in mammals
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
CA2540059C (en) * 2003-09-26 2013-08-06 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
ATE504288T1 (de) * 2003-09-26 2011-04-15 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
KR20060092255A (ko) * 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
KR20120106757A (ko) * 2003-09-26 2012-09-26 알자 코포레이션 오피오이드 및 비오피오이드 진통제의 제어 방출 제제
KR101118930B1 (ko) 2003-11-14 2012-03-14 아지노모토 가부시키가이샤 페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제
WO2005097131A2 (en) * 2004-04-09 2005-10-20 Janssen Pharmaceutica N.V. Intermittent dosing regimen for the treatment of overweight with mtp-inhibitors
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
EP1912626B1 (en) * 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Dosage forms with improved bioavailability
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2010143199A1 (en) 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
CN1068000C (zh) * 1994-10-27 2001-07-04 詹森药业有限公司 阿朴脂蛋白-b合成抑制剂

Also Published As

Publication number Publication date
CA2307097A1 (en) 1999-05-14
WO1999022738A1 (en) 1999-05-14
HUP0004139A3 (en) 2002-03-28
HUP0004139A2 (hu) 2002-02-28
AR013739A1 (es) 2001-01-10
US6342245B1 (en) 2002-01-29
AU746890B2 (en) 2002-05-02
EP1028730B1 (en) 2002-04-17
NO20002279D0 (no) 2000-04-28
CN1278175A (zh) 2000-12-27
JP2001521899A (ja) 2001-11-13
KR20010023729A (ko) 2001-03-26
PL340305A1 (en) 2001-01-29
BR9814109A (pt) 2000-10-03
SK5972000A3 (en) 2000-12-11
DE69804994D1 (de) 2002-05-23
EP1028730A1 (en) 2000-08-23
KR20010023661A (ko) 2001-03-26
NO20002279L (no) 2000-04-28
AU1157699A (en) 1999-05-24
ATE216238T1 (de) 2002-05-15
ZA989997B (en) 2000-05-02
BG104338A (en) 2000-12-29
NZ503413A (en) 2001-06-29

Similar Documents

Publication Publication Date Title
EE03902B1 (et) Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
EE200000186A (et) Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend
EE04991B1 (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
EE04996B1 (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
EE04042B1 (et) Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks
FI962901L (fi) Uudelleendispergoitava dispersiojauheseos, sen valmistusmenetelmä ja sen käyttö
WO2002043702A3 (en) Pharmaceutical compositions for inhalation
FI962900L (fi) Redispergoituvat, piimodifioidut dispersiojauheseokset, menetelmä niiden valmistamiseksi ja niiden käyttö
AU5936400A (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
HUP0003990A3 (en) Methods of treating capsules and dry, powdered pharmaceutical formulations
FI954143L (fi) Kiinteitä lipidihiukkasia, bioaktiivisten aineiden hiukkasia, menetelmiä niiden valmistamiseksi ja niiden käyttö
IL143580A0 (en) Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof
IL116674A (en) Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
HUP0104687A3 (en) Methods for preparing coated drug particles and pharmaceutical formulations thereof
FI953898A7 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
HUP0003690A3 (en) Polymeric derivatives of camptothecins, process for their preparation and pharmaceutical compositions containing them
AU1606600A (en) Apparatus and method for desiccating and deagglomerating wet, particulate materials
HUP0100266A3 (en) 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing the compounds and their preparations
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP0200309A3 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
EE03552B1 (et) Tahke doseerimisvorm, selle valmistamismeetod, seda sisaldav produkt, tablett ja farmatseutiline pakend ning tsisapriidisoolade kasutamine
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
FI945975L (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod